PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group

Nathalie L Albert; Norbert Galldiks; Benjamin M Ellingson; Martin J van den Bent; Susan M Chang; Francesco Cicone; John de Groot; Eng-Siew Koh; Ian Law; Emilie Le Rhun; Maximilian J Mair; Giuseppe Minniti; Roberta Rudà; Andrew M Scott; Susan C Short; Marion Smits; Bogdana Suchorska; Nelleke Tolboom; Tatjana Traub-Weidinger; Joerg-Christian Tonn; Antoine Verger; Michael Weller; Patrick Y Wen; Matthias Preusser

doi:10.1016/S1470-2045(23)00525-9

PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group

Lancet Oncol. 2024 Jan;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9.

Authors

Nathalie L Albert¹, Norbert Galldiks², Benjamin M Ellingson³, Martin J van den Bent⁴, Susan M Chang⁵, Francesco Cicone⁶, John de Groot⁵, Eng-Siew Koh⁷, Ian Law⁸, Emilie Le Rhun⁹, Maximilian J Mair¹⁰, Giuseppe Minniti¹¹, Roberta Rudà¹², Andrew M Scott¹³, Susan C Short¹⁴, Marion Smits¹⁵, Bogdana Suchorska¹⁶, Nelleke Tolboom¹⁷, Tatjana Traub-Weidinger¹⁸, Joerg-Christian Tonn¹⁹, Antoine Verger²⁰, Michael Weller²¹, Patrick Y Wen²², Matthias Preusser²³

Affiliations

¹ Department of Nuclear Medicine, LMU Hospital, LMU Munich, Munich, Germany.
² Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany; Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Cologne, Germany.
³ UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
⁴ The Brain Tumour Center at the Erasmus MC Cancer Institute, Rotterdam, Netherlands.
⁵ Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
⁶ Nuclear Medicine Unit, Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy.
⁷ Department of Radiation Oncology, Liverpool and Macarthur Cancer Therapy Centre, Liverpool, NSW, Australia; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia.
⁸ Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, Denmark.
⁹ Department of Neurosurgery, University Hospital Zurich, Zurich, Switzerland; Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
¹⁰ Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
¹¹ Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy; IRCCS Neuromed, Pozzilli IS, Italy.
¹² Division of Neuro-Oncology, Department of Neuroscience, University of Turin and City of Health and Science of Turin, Turin, Italy.
¹³ Department of Molecular Imaging and Therapy, Austin Health and University of Melbourne, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
¹⁴ Leeds Institute of Medical Research at St James's, The University of Leeds, Leeds, UK.
¹⁵ Department of Radiology & Nuclear Medicine, Erasmus MC-University Medical Centre Rotterdam, Rotterdam, Netherlands; Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Medical Delta, Delft, Netherlands.
¹⁶ Department of Neurosurgery, Heidelberg University Hospital, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
¹⁷ Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
¹⁸ Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
¹⁹ Department of Neurosurgery, LMU Hospital, LMU Munich, Munich, Germany.
²⁰ Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHRU Nancy and IADI INSERM UMR 1254, Universitè de Lorraine, Nancy, France.
²¹ Department of Neurology, University Hospital Zurich, Zurich, Switzerland; Department of Neurology, University of Zurich, Zurich, Switzerland.
²² Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
²³ Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: matthias.preusser@meduniwien.ac.at.

PMID: 38181810
DOI: 10.1016/S1470-2045(23)00525-9

Abstract

Response Assessment in Neuro-Oncology (RANO) response criteria have been established and were updated in 2023 for MRI-based response evaluation of diffuse gliomas in clinical trials. In addition, PET-based imaging with amino acid tracers is increasingly considered for disease monitoring in both clinical practice and clinical trials. So far, a standardised framework defining timepoints for baseline and follow-up investigations and response evaluation criteria for PET imaging of diffuse gliomas has not been established. Therefore, in this Policy Review, we propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas as defined in the 2021 WHO classification of tumours of the central nervous system. These proposed PET RANO criteria provide a conceptual framework that facilitates the structured implementation of PET imaging into clinical research and, ultimately, clinical routine. To this end, the PET RANO 1.0 criteria are intended to encourage specific investigations of amino acid PET imaging of gliomas.

Publication types

Review

MeSH terms

Amino Acids
Glioma* / diagnostic imaging
Glioma* / therapy
Humans
Internal Medicine
Neurology*
Positron-Emission Tomography
Transcription Factors

Substances

Amino Acids
Transcription Factors